While PET/MPI is widely viewed to be superior to SPECT, not all tracers are equal. Considered an optimal tracer for Myocardial Perfusion, N-13 Ammonia provides1
1. Fiechter et al., J Nucl Med 2012; 53: 1230-1234
Using N-13 Ammonia for quantitative imaging offers significant diagnostic advantages:
Risk Stratification using Myocardial Blood Flow (MBF)
Research shows that N-13 Ammonia with MBF is a strong predictor of patient outcomes. A study on the long-term prognostic value of N-13 Ammonia with MBF demonstrated that an abnormal MBF, regardless of normal or abnormal perfusion images, was associated with higher adverse cardiac events. Conversely, a normal perfusion along with a normal MBF suggested a 3-year "warranty" period.1
When performed with N-13 Ammonia, quantitative imaging results in more accurate patient risk reclassification. In the study shown here, 51% of the patients initially presenting in the intermediate cardiac risk category were reclassified after MBF with Ammonia N-13.
1. Murthy V.L. et. al. Circulation. 2011 Nov 15; 124(20): 2215-2224
Multiple studies have demonstrated the clinical and diagnostic advantages of PET MPI with N-13 Ammonia for a variety of specific patient profiles and conditions.